<code id='CBE8E2E367'></code><style id='CBE8E2E367'></style>
    • <acronym id='CBE8E2E367'></acronym>
      <center id='CBE8E2E367'><center id='CBE8E2E367'><tfoot id='CBE8E2E367'></tfoot></center><abbr id='CBE8E2E367'><dir id='CBE8E2E367'><tfoot id='CBE8E2E367'></tfoot><noframes id='CBE8E2E367'>

    • <optgroup id='CBE8E2E367'><strike id='CBE8E2E367'><sup id='CBE8E2E367'></sup></strike><code id='CBE8E2E367'></code></optgroup>
        1. <b id='CBE8E2E367'><label id='CBE8E2E367'><select id='CBE8E2E367'><dt id='CBE8E2E367'><span id='CBE8E2E367'></span></dt></select></label></b><u id='CBE8E2E367'></u>
          <i id='CBE8E2E367'><strike id='CBE8E2E367'><tt id='CBE8E2E367'><pre id='CBE8E2E367'></pre></tt></strike></i>

          Home / fashion / knowledge

          knowledge


          knowledge

          author:leisure time    Page View:558

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In